Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA)

Organization & Developments: Comera Life Sciences

Parents

Comera’s SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Preclinical stage life sciences company focused on developing an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore.
The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.